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Receptor for advanced glycation end-products-
mediated inﬂammation and diabetic vascular
complications
Exposure of amino residue of proteins to reducing sugars, such
as glucose, glucose 6-phosphate, fructose, ribose and intermedi-
ate aldehydes, results in non-enzymatic glycation, which forms
reversible Schiff bases and Amadori compounds. A series of fur-
ther complex molecular rearrangements then yield irreversible
advanced glycation end-products (AGE). The aldehydes, highly
reactive AGE precursors, are produced by both enzymatic and
non-enzymatic pathways. The enzymatic pathways include a
route of myeloperoxidase in inﬂammatory cells, such as acti-
vated macrophages, which produces hypochlorite, then reacting
with serine to generate glycolaldehyde. Methylglyoxal (MGO) is
generated by the degeneration of triose phosphate intermediates
in the glycolytic system. 3-Deoxyglucosone (3DG) is produced
by fructosamine-3-kinase from fructoselysine, an Amadori com-
pound. Another route is the formation of aldehydes, glucosone
and glyoxal from peroxynitrite (ONOO)) and superoxide anion
radical (O2
)·). Non-enzymatic pathways include glucose auto-
oxidation resulting in the formation of glyoxal and hydrolysis of
Amadori rearrangement products yielding 3DG. In diabetes,
uncontrolled and sustained hyperglycemia superdrives this
glycation reaction, and AGE accumulate in the circulation and
various tissues. A hypothesis that interactions between AGE and
the receptor for AGE (RAGE) are the crucial cause of diabetic
vascular derangements has emerged from experiments with vas-
cular endothelial cells (EC), pericytes and renal mesangial cells
in culture and from AGE inhibitor-treated or RAGE-gene
manipulated animals1,2. Among a number of AGE components,
carboxylmethyllysine (CML) and AGE generated from glycer-
aldehyde or glycolaldehyde were found to bind RAGE and
subsequently elicit RAGE signaling.
RAGE consists of an extracellular region, a transmembrane
domain and a 43-amino acid short cytoplasmic tail. The extra-
cellular region is composed of three immunoglobulin-like
domains: one V-type and two C-type domains. The V-type
domain of RAGE was found to interact with AGE, and its lack
of N-glycosylation modiﬁcation enhanced the binding afﬁnity to
AGE. The possible mechanism of the binding includes charge
association and subsequent stabilization of the complex with
hydrophobic interaction after conformational changes of RAGE
V-type domain3. This concept is supported by the fact that low
molecular weight heparin (LMWH; approximately 5 kDa and
negative charged) binds RAGE and inhibits AGE–RAGE associ-
ation, resulting in silencing RAGE activation of NFjB2. In
EC, RAGE signaling caused by AGE could induce expressions
of genes for vascular endothelial growth factor (VEGF) and
for vascular cell adhesion molecule-1 (VCAM-1), leading
to enhancement of vascular permeability, angiogenesis, and
local inﬂammation. The endothelial–mesenchymal transition
(EndoMT) was also induced by this system4. Secretion of various
cytokines, such as tumor necrosis factor-a (TNF-a), interleukin-
1b (IL-1b), IL-6 and monocyte chemotactic protein-1 (MCP-1),
were induced by the AGE–RAGE signaling in monocytes and
macrophages. RAGE promoter assays showed that RAGE sig-
naling by AGE promoted the transcriptional upregulation of the
RAGE gene by itself through an activation of NFjB. TNF-a
and estrogen also enhanced a transcription of the RAGE gene
through an activation of NFjB and a transcription factor Sp1,
respectively. Recently, the mammalian homolog of the Droso-
phila gene, diaphanous 1 (mDia1), has been identiﬁed as a
direct binding molecule with an intracellular domain of RAGE
and as a part of the machinery of RAGE intracellular signaling.
mDia1, one of the formin homology proteins, exists widely from
yeast to mammals and is known to link with cell division, polar-
ity formation and movements by actin polymerization.
Because other pro-inﬂammatory ligands of RAGE have
been identiﬁed, including high-mobility group box protein 1
(HMGB1), advanced oxidation protein products (AOPP), S100-
calcium binding (S100) proteins, CD11b (Mac-1), amyloid
b-proteins and complement C3a, lipopolysaccharides (LPS), and
phosphatidylserine on the surface of apoptotic cells, RAGE is
considered a member of pattern recognition receptors (PRR),
such as toll-like receptors (TLR), actively participating in inﬂam-
mation, diabetic vascular complications and atherosclerosis
(Figure 1). HMGB1 is a nuclear protein stabilizing nucleosome
formation and facilitating transcription. Though HMGB1 lacks
a classical secretion signal, it is known as a strong inﬂammatory
mediator from necrotic cells by passive leakage and can be
actively secreted by activated monocytes, macrophages, dendritic
cells (DC), natural killer (NK) cells and EC. HMGB1 association
with RAGE is enhanced by the presence of CpG DNA, and
HMGB1 directly binds LPS and IL-1b. The formation of the
complex with other pro-inﬂammatory molecules further aggra-
vates activation of RAGE signaling. TLR2 and TLR4 have also
been identiﬁed to be involved in HMGB1-induced cellular sig-
naling. Hence, the interplay of RAGE ⁄TLR receptors and their
signaling pathways exacerbates NFjB activation and pro-inﬂam-
matory reactions. As anti-inﬂammatory machinery, the lectin
domain of thrombomodulin (TM) can bind HMGB1 and
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thereby blocks HMGB1 interaction with RAGE. S100 proteins
are a family of over 20 proteins sharing structural similarity with
their two EF-hand Ca++ binding domains ﬂanked by a-helices;
among them, S100A1, A2, A4, A5, A6, A7 ⁄A7A, A8 ⁄A9, A11,
A12, B and P could bind RAGE. Their higher oligomerization
states lead to RAGE activation. A recent report showed CML-
modiﬁed S100A8 ⁄A9 strongly activated intestinal inﬂammatory
responses through RAGE, suggesting more complex varieties
of RAGE ligands modiﬁed by glycation reactions. Although
deglycosylation sensitizes RAGE to bind AGE, carboxylated
N-glycans on RAGE increase the binding afﬁnity with S100A8 ⁄9,
as well as HMGB1. S100A8 ⁄A9 was also shown to interact with
TLR4. CD11b (Mac-1) is a cell surface molecule expressed
on neutrophils, monocytes, macrophages, dendritic cells and
NK cells. It mediates the interaction of RAGE together with
endothelial counter-receptors, such as intercellular adhesion
molecule 1 (ICAM-1). With this adhesion, RAGE thus mediates
recruitment and accumulation of the immune cells into inﬂam-
matory foci. The activation of RAGE on T cells leads to the
differentiation of Th1 cells, thus playing a role in balancing Th1
and Th2 immunity. RAGE triggers the maturation of DC to
migrate to draining lymph nodes.
It is reported that the binding of HMGB1 to RAGE induces
RAGE shedding by a disintegrin and metalloproteinase 10
(ADAM10), as well as an intracellular signal transduction, repre-
senting one pathway for autodownregulation of RAGE-mediated
cellular activation. The cleavage of the membrane-bound full-
length RAGE (signal transducer) yields soluble RAGE (sRAGE),
which could work as a decoy receptor against ligand-RAGE
interactions. In the strict sense of the word, sRAGE is a hetero-
geneous population of total sRAGE proteins, including soluble
splice variants of RAGE and the proteinase-cleaved forms of
membrane-bound RAGE and of the soluble variants. Endoge-
nous secretory RAGE (esRAGE)5 is one of the major splice vari-
ants of RAGE existing in the circulation and also being widely
distributed to the cell surface and cytoplasm of neurons, EC,
pneumocytes, mesothelium, pancreatic b-cells, monocytes, mac-
rophages, salivary glands, digestive tracts, renal tubules, prostate,
skin, thyroid and bronchioles. The sRAGE is thought to act
locally and systemically as a decoy receptor. The administration
of sRAGE has been shown to attenuate experimental animal
models of various RAGE-related diseases, such as atherosclero-
sis. sRAGE ⁄esRAGE could also modulate inﬂammatory reac-
tions. Reinforcing the ectodomain shedding will decrease a total
amount and expression of full-length membrane-bound RAGE
and will reciprocally increase an amount of sRAGE, this can
control AGE-RAGE signaling and subsequent cellular and tissue
derangement. Recent clinical studies have focused on the signiﬁ-
cance of circulating sRAGE in a variety of pathophysiological
conditions. Above all, ﬁndings in both type 1 and type 2 dia-
betic patients are quite confusing, and have been reported to be
both increased and decreased. The presence of renal insufﬁ-
ciency can affect circulating sRAGE level, which might explain
the controversial ﬁndings of sRAGE in diabetes.
Considered together, the suppression of RAGE action might
be beneﬁcial for preventing and slowing down the development
of diabetic vascular complications, atherosclerosis and inﬂamma-
tion. Potential candidates for this purpose might include a
downregulator of full-length membrane-bound RAGE, RAGE-
speciﬁc antagonists, blockers against RAGE intracellular signal-
ing, enhancers of esRAGE production, supplementation of
esRAGE or sRAGE and an inducer of RAGE shedding.
Angiotensin-converting enzyme inhibitor, thiazolidine, and
statin are reported to stimulate esRAGE ⁄ sRAGE secretion.
LMWH, the depolymerized and fractionated derivative of hepa-
rin, has been shown to work as a RAGE antagonist by inhibiting
AGE-RAGE signaling2. At present, TTP488 is a speciﬁc RAGE
antagonist under clinical trials in the USA and its efﬁcacy
is anticipated. It will be interesting in the future to develop
new devices and remedies that control the RAGE ectodomain
shedding.
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Figure 1 | Receptor for advanced glycation end-products (RAGE) as a
member of pattern-recognition receptors (PRR) participating in inﬂam-
mation and diabetic vascular complications. AGE, advanced glycation
end-products; AOPP, advanced oxidation protein products; esRAGE,
endogenous secretory receptor for advanced glycation end-products;
HMGB1, high-mobility group box protein 1; LPS, lipopolysaccharides;
sRAGE, soluble receptor for advanced glycation end-products; TLR,
toll-like receptors.
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